跳至主要内容
临床试验/NCT05133999
NCT05133999已完成不适用

Iron, Transferrin and Retinopathy of Prematurity (ROP): Towards New Pathophysiological Mechanisms.

Assistance Publique - Hôpitaux de Paris3 个研究点 分布在 1 个国家目标入组 175 人开始时间: 2022年4月28日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
175
试验地点
3
主要终点
Levels of transferrin saturation in plasma at 1 week of life

研究概览

简要总结

The purpose of this study is to determine whether increased transferrin saturation in plasma (that reflects iron overload and/or low transferrin) is an independent risk factor for ROP development and severity.

Preterm infants born at <31 week's post-menstrual age (PMA) or ≤1250g of birth weight will be included. Iron parameters in plasma will be measured during the first month of life. Retinopathy of prematurity (ROP) will be screened as currently recommended. The relationship between plasma iron parameters and ROP development and/or severity will be established.

详细描述

The incidence of ROP, the main cause of vision impairment in children, is increasing parallel to the recent changes in practices targeting higher oxygen saturation in preterm babies in many countries following the publication of five trials that showed higher rates of death with lower oxygen saturations. The main risk factor for ROP development is oxygen excess. Oxygen contributes to the formation of reactive oxygen species and to lipid peroxidation which leads to vasoconstriction, vascular cytotoxicity, and arrest of vascular development causing ischemia of retinal neurons, thereby promoting the development of ROP.

90% of extremely low birth weight infants need red blood cell transfusions (RBCT) due to their immature erythropoiesis, frequent blood sampling and small circulating blood volume. RBCT are a major source of iron overload and ferritin plasma levels may remain elevated for several weeks after transfusions. It has been shown that blood transfusion is a risk factor of ROP in preterm infants. However, whether this relationship is mediated by an increased iron load remains controversial.

Only two studies, conducted before the 2000s, identified plasma iron overload as a risk factor for ROP. These studies with a limited number of patients, showed contradictory results, failing to draw a conclusion.

Excess iron worsens oxidative stress. Iron catalyzes the Fenton reaction which leads to the formation of reactive oxygen species. In addition a transferrin deficiency (the main iron chelator) has been suggested in premature infants. The oxidative stress observed in ROP could therefore be the consequence not only of oxygen therapy but also of iron overload.

The main objective of this study is to determine whether increased transferrin saturation in plasma (that reflects iron overload and/or low transferrin) is an independent risk factor for ROP development and severity.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
24 Weeks 至 31 Weeks(Child)
性别
All
接受健康志愿者

入选标准

  • All infants born at <31 week's post-menstrual age (PMA) or ≤1250g of birthweight
  • Admitted at two neonatology departments (level III) from birth
  • With non-opposition consent of two parents

排除标准

  • Congenital malformation
  • Life-threatening condition (not expected to survive more than a few days)
  • Absence of health care protection.

研究组 & 干预措施

Preterm infants

infants born at <31 week's post-menstrual age (PMA) or ≤1250g of birth weight

干预措施: Plasma determination of iron, transferrin and ferritin (Biological)

Preterm infants

infants born at <31 week's post-menstrual age (PMA) or ≤1250g of birth weight

干预措施: Fundus Examination by wide field digital imaging camera (PanocamTM camera) (Other)

结局指标

主要结局

Levels of transferrin saturation in plasma at 1 week of life

时间窗: at 1 week of life

Blood dosage

ROP screening

时间窗: From 31 to 45 weeks' post menstrual age (PMA) [= (term + 4 weeks of life)].

Presence of ROP development (any stage / any zone in at least one eye) during follow-up.

次要结局

  • Levels of iron(at birth, 2, 3, and 4 weeks of life)
  • Levels of transferrin(at birth, 2, 3, and 4 weeks of life)
  • Number of each intervention(during follow-up about 5 months, up to 45 weeks' PMA)
  • Levels of ferritin(at birth, 2, 3, and 4 weeks of life)
  • ROP's highest stage(during follow-up about 5 months, up to 45 weeks' PMA)
  • Need of treatment for ROP(during follow-up about 5 months, up to 45 weeks' PMA)
  • Death or presence of severe co-morbidities in preterm infant(At 36 weeks' PMA)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验